2023
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. European Urology Oncology 2023, 6: 516-524. PMID: 37087309, PMCID: PMC10587361, DOI: 10.1016/j.euo.2023.03.008.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerNeoadjuvant chemotherapyCooperative group trialsCell-free DNA methylationProspective cooperative group trialsPathologic responseBladder cancerRadical cystectomyNAC responseChemotherapy responseTreatment responseGroup trialsCycles of chemotherapyNeoadjuvant chemotherapy responseAdvanced bladder cancerStandard of careBladder cancer patientsIndependent predictive abilityGene expression signaturesMetastatic diseaseCancer patientsPredictive biomarkersPathologic respondersCurrent exploratory analysisInvasive approach
2022
Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients
Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.Peer-Reviewed Original ResearchConceptsProstate cancer patientsCOVID-19 outcomesCancer patientsPoor COVID-19 outcomesAndrogen-androgen receptorExpression of TMPRSS2COVID-19 infectionSARS-CoV-2Directed therapyMean hospitalizationPCa patientsHospitalization ratesPCa casesRetrospective analysisOutcome differencesPatientsDefinitive conclusionsStatistical significanceData generate hypothesesHospitalizationTherapyTMPRSS2Cellular entryOutcomesARDTCell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314. Journal Of Clinical Oncology 2022, 40: 4506-4506. DOI: 10.1200/jco.2022.40.16_suppl.4506.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBladder cancer patientsPathologic responseTreatment responseCell-free DNA methylationCancer patientsMuscle-invasive bladder cancer patientsMuscle-invasive bladder cancerCycles of chemotherapyStandard neoadjuvant chemotherapyCooperative group trialsStandard of careProspective cooperative group trialsIndependent predictive abilityRadical cystectomyPredictive biomarkersPathologic respondersBladder cancerGroup trialsMR scoreBlood samplesChemotherapyPatientsPlasma samplesResponse scores
2021
PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES
Shore N, Iguchi T, Villers A, Alcaraz A, Gomez-Veiga F, Stenzl A, Azad A, Alekseev B, Petrylak D, Szmulewitz R, Holzbeierlein J, Rosbrook B, Zohren F, Haas G, Gourgioti G, El-Chaar N, Armstrong A. PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES. Journal Of Urology 2021, 206: e585-e585. DOI: 10.1097/ju.0000000000002038.07.Peer-Reviewed Original Research
2016
The impact of androgen deprivation and pelvic radiation on the development of bladder cancer.
Hafez N, Wang R, Hurwitz M, Ma X, Petrylak D. The impact of androgen deprivation and pelvic radiation on the development of bladder cancer. Journal Of Clinical Oncology 2016, 34: 439-439. DOI: 10.1200/jco.2016.34.2_suppl.439.Peer-Reviewed Original ResearchAndrogen deprivation therapyUrothelial bladder cancerProstate cancer patientsSecondary bladder cancerBladder cancerCancer patientsRadiation therapyAndrogen deprivationProstate cancerRecurrent urothelial bladder cancerElderly prostate cancer patientsCox proportional modelingRetrospective cohort studyKaplan-Meier analysisSEER-Medicare databaseSimilar patient populationsProstate cancer treatmentPrimary prostate cancerDeprivation therapyMedian followPelvic radiationCohort studyMale predilectionProportional modelingPatient population
2015
2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo
Petrylak D, Eigl B, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar S, Sternberg C, Retz M, Blumenstein B, Jacobs C, Stewart P, Bellmunt J. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. European Journal Of Cancer 2015, 51: s525. DOI: 10.1016/s0959-8049(16)31454-x.Peer-Reviewed Original Research
2014
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.
Halabi S, Kelly W, Zhou H, Armstrong A, Quinn D, Fizazi K, Solomon N, Tannock I, Petrylak D, Morris M, Small E. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. Journal Of Clinical Oncology 2014, 32: 5002-5002. DOI: 10.1200/jco.2014.32.15_suppl.5002.Peer-Reviewed Original Research
2008
Efficacy and safety of docetaxel in the elderly
Mohile S, Berenji F, Sahasrabudhe D, Morrow G, Petrylak D. Efficacy and safety of docetaxel in the elderly. Aging Health 2008, 4: 113-127. DOI: 10.2217/1745509x.4.2.113.Peer-Reviewed Original ResearchElderly patientsWeekly dosingSide effectsSafety of docetaxelPhase II studyCommon side effectsElderly cancer patientsIncidence of myelosuppressionMost side effectsSolid tumor malignanciesEffective chemotherapeutic agentSignificant age-related effectsDermatologic toxicitiesII studyAdverse eventsDosing schedulesHypersensitivity reactionsCancer patientsFluid retentionAge-related effectsDose reductionTreatment planCancer subtypesTumor malignancyChemotherapeutic agents
2007
605: Androgen Independent Prostate Cancer (AIPC) Patients who Receive Sipuleucel-T Followed by Docetaxel Have Prolonged Survival
Petrylak D, Schellhammer P, Small E, Frohlich M. 605: Androgen Independent Prostate Cancer (AIPC) Patients who Receive Sipuleucel-T Followed by Docetaxel Have Prolonged Survival. Journal Of Urology 2007, 177: 202. DOI: 10.1016/s0022-5347(18)30845-0.Peer-Reviewed Original Research
2005
A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaula R, Beer T, Eisenberger M. A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. Journal Of Clinical Oncology 2005, 23: 4565-4565. DOI: 10.1200/jco.2005.23.16_suppl.4565.Peer-Reviewed Original Research
2004
Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola R, Beer T, Eisenberger M. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Journal Of Clinical Oncology 2004, 22: 4649-4649. DOI: 10.1200/jco.2004.22.14_suppl.4649.Peer-Reviewed Original ResearchAdjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial
Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola R, Beer T, Eisenberger M. Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Journal Of Clinical Oncology 2004, 22: 4649-4649. DOI: 10.1200/jco.2004.22.90140.4649.Peer-Reviewed Original Research
2000
Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients
Lee N, Fawaaz R, Olsson C, Benson M, Petrylak D, Schiff P, Bagiella E, Singh A, Ennis R. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1443-1446. PMID: 11121646, DOI: 10.1016/s0360-3016(00)00785-9.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive bone scanRadionuclide bone scanBone scanClinical stageLow-risk groupGleason scorePositive BSIndependent predictorsProstate cancerNegative bone scanSignificant independent predictorsProstate cancer patientsSame risk groupProstate cancer biopsiesPathologic reviewStaging evaluationConsecutive patientsGleason 2Cancer patientsVs. 0Odds ratioRisk groupsPatientsCancer biopsies
1999
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Seminars In Oncology 1999, 26: 55-60. PMID: 10604271.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerProstate cancerHormone-refractory prostate cancer patientsProstate-specific antigen levelRandomized phase III trialEnd pointPrimary end pointSecondary end pointsPhase III trialsSingle institution experienceSide effect profileSouthwest Oncology GroupCombination of mitoxantroneProstate cancer patientsStandard armIII trialsOncology GroupAssessment of qualityClinical outcomesEffect profileRandomized trialsTreatment armsAntigen levelsInstitution experienceCancer patients